| Literature DB >> 28396702 |
Ken Declerck1, Sylvie Remy2,3, Christine Wohlfahrt-Veje4, Katharina M Main4, Guy Van Camp5, Greet Schoeters3,6,7, Wim Vanden Berghe1, Helle R Andersen7.
Abstract
BACKGROUND: Prenatal environmental conditions may influence disease risk in later life. We previously found a gene-environment interaction between the paraoxonase 1 (PON1) Q192R genotype and prenatal pesticide exposure leading to an adverse cardio-metabolic risk profile at school age. However, the molecular mechanisms involved have not yet been resolved. It was hypothesized that epigenetics might be involved. The aim of the present study was therefore to investigate whether DNA methylation patterns in blood cells were related to prenatal pesticide exposure level, PON1 Q192R genotype, and associated metabolic effects observed in the children.Entities:
Keywords: Cardio-metabolic health; DNA methylation; Illumina 450 K methylation array; PON1 Q192R genotype; Paraoxonase 1; Prenatal pesticide exposure
Mesh:
Substances:
Year: 2017 PMID: 28396702 PMCID: PMC5382380 DOI: 10.1186/s13148-017-0336-4
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 6.551
Population characteristics and anthropometric data for 48 pre-pubertal children examined at age 6–11 years stratified by PON1 Q192R genotype and prenatal pesticide exposure
|
|
| |||
|---|---|---|---|---|
| Unexposed | Exposed | Unexposed | Exposed | |
|
| 11 | 13 | 12 | 12 |
| Female sex | 5 (45.5) | 7 (53.8) | 6 (50.0) | 6 (50.0) |
| Maternal smoking in pregnancy | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| SESa | 7/4 (63.6/36.4) | 3/10 (23.1/76.9)* | 5/7 (41.7/58.3) | 2/10 (16.7/83.3) |
| Birth weight (g) | 3640 (2600; 5412) | 3382 (2750; 4573) | 3789 (2984; 4345) | 3500 (2900; 3914)* |
| Gestational age (days) | 276 (257; 291) | 283 (265; 295) | 283 (261; 298) | 281 (266; 291) |
| Age (years) | 7.6 (6.2; 9.8) | 8.4 (6.7; 10,0) | 7.8 (6.6; 9.5) | 7.7 (7.1; 9.4) |
| Height (cm) | 133.3 (117.3; 145.2) | 130.3 (109.7; 139.2) | 130.9 (113.7; 149.1) | 128.6 (119.3; 142,5) |
| Weight (kg) | 30.9 (18.7; 38.0) | 28.3 (18.0; 30.7) | 26.3 (19.9; 36.5) | 27.4 (19.5; 37.8) |
| BMI (kg/m2) | 16.2 (13.7; 20.5) | 15.3 (14.9; 18.3) | 15.5 (13.8; 16.9) | 15.7 (13.8; 19.7) |
| BMI | 0.66 (−1.03; 3.21) | −0.18 (−0.80; 1.49) | −0.04 (−1.31; 0.89) | −0.01 (−0.98; 3.14) |
| Delta BMI | −0.45 (−2.15; 2.97) | −0.71 (−2.57; 1.87) | −0.56 (−2.52; 1.03) | 0.95 (−2.08; 2.97)* |
| Abdominal circumference (cm) | 60.4 (52.0; 75.8) | 58.7 (52.1; 66.8) | 58.3 (52.0; 68.1) | 60.8 (51.8; 70.6)* |
| Sum of four skin folds (mm) | 38.4 (27.1; 85.4) | 33.6 (25.4; 54.5) | 34.0 (20.2; 45.2) | 44.6 (28.8; 72.0)* |
| Systolic blood pressure (mmHg) | 98.7 (93.7; 110.4) | 97.2 (84.3; 105.3) | 99.7 (84.7; 106.8) | 101.7 (91.0; 108.6) |
| Diastolic blood pressure (mmHg) | 54.7 (46.0; 69.9) | 56.2 (46.0; 62.0) | 56.3 (49.3; 69.1) | 63.0 (57.3; 73.1)** |
| Leptin (ng/ml) | 1.47 (0.70; 9.18) | 4.40 (0.60; 15.29) | 1.41 (0.67; 5.90) | 4.69 (1.79; 12.25)** |
| Insulin (ng/ml) | 0.36 (0.22; 1.15) | 0.52 (0.23; 2.55) | 0.34 (0.16; 1.62) | 1.11 (0.24; 7.10)* |
| Paraoxonase activity (nmol/min/ml) | 27.5 (9.9; 38.0) | 30.9 (21.0; 38.9) | 58.6 (41.9; 68.7) | 59.6 (50.3; 71.5) |
a SES socioeconomic status (social class 1–3/4–5). Differences between unexposed and exposed children for each PON1 Q192R genotype were tested using Mann-Whitney U test for continuous variables and Fisher’s exact test (dichotomous variables) or Likelihood ratio (categorical variables with > 2 categories). *P value ≤ 0.05, **P value ≤ 0.01. Values are presented as median (5–95%) for continuous variables and as N (%) for categorical variables
Fig. 1Analysis workflow. Differentially methylated genes were detected using a single CpG and a region-based approach. Only sig-DMPs and sig-DMRs were selected in which the pesticide exposed QR carrier group was either hyper- or hypomethylated in comparison with the other groups (interesting profile). By overlapping the sig-DMPs with the sig-DMRs a high confidence list of differentially methylated genes could be generated
Fig. 2Heatmap clustering representation of the sig-DMPs. Heatmap of the methylation values from the sig-DMPs showing a clear cluster of prenatal pesticide exposed PON1-192 R-carrier samples (orange group). Hierarchical clustering is based on the euclidean distance and average linkage metric. Higher methylation values are colored in yellow, while lower methylation values are colored in blue
Fig. 3Correlation between the Illumina 450 K beta values and the pyrosequencing methylation percentages. The Pearson’s correlation coefficient for each CpG probe is indicated between brackets. CpG probes cg00840332, cg19594666, and cg26814075 are located in the LEP gene, cg17172683, cg11552903, and cg18444763 in the GPR39 gene, cg01412654 in the PPARG gene, and cg06908202, and cg16919708 in the OPCML gene
Fig. 4Genomic location of sig-DMPs. DMPs were mapped to gene elements (top left), CpG islands (top right), and chromatin state segmentations (bottom). Asterisks indicate significant enrichment or depletion in comparison with all Illumina probes (gray bars) measured by the Fisher’s exact test (P value < 0.05). Sig–DMPs where the interaction term was significant (blue bars) showed an enrichment in promoter regions and CpG islands. Sig-DMPs where no interaction was seen (orange bars) showed no significant enrichment or depletion in a particular genomic region
Significant enriched Ingenuity canonical pathways
| Rank | Ingenuity canonical pathways | −log( | Ratio | Hyper-genes | Hypo-genes |
|---|---|---|---|---|---|
| 1 | Dopamine-DARPP32 Feedback in cAMP signaling | 3.98 | 0.07 |
|
|
| 2 | Corticotropin releasing Hormone signaling | 2.74 | 0.07 |
|
|
| 3 | nNOS signaling in neurons | 2.61 | 0.11 |
|
|
| 4 | CDK5 signaling | 2.41 | 0.07 |
|
|
| 5 | Neuregulin signaling | 2.06 | 0.07 |
|
|
| 6 | PCP pathway | 2.06 | 0.08 |
| |
| 7 | Maturity onset diabetes of young (MODY) signaling | 2.03 | 0.14 |
|
|
| 8 | Regulation of eIF4 and p70S6K signaling | 2.02 | 0.05 |
|
|
| 9 | mTOR signaling | 1.85 | 0.05 |
|
|
| 10 | Amyotrophic lateral sclerosis signaling | 1.84 | 0.06 |
|
|
| 11 | NF-κB activation by viruses | 1.8 | 0.07 |
| |
| 12 | Phosphatidylethanolamine biosynthesis III | 1.7 | 1 |
| |
| 13 | Role of CHK proteins in cell cycle checkpoint control | 1.61 | 0.07 |
|
|
| 14 | Synaptic long-term depression | 1.6 | 0.05 |
|
|
| 15 | ErbB signaling | 1.53 | 0.06 |
|
|
| 16 | Type II diabetes mellitus signaling | 1.51 | 0.05 |
|
|
| 17 | G beta gamma signaling | 1.49 | 0.06 |
|
|
| 18 | p70S6K signaling | 1.48 | 0.05 |
|
|
| 19 | Role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis | 1.47 | 0.04 |
| |
| 20 | Molecular mechanisms of cancer | 1.46 | 0.04 |
| |
| 21 | nNOS signaling in skeletal muscle cells | 1.45 | 0.13 |
|
|
| 22 | Factors promoting cardiogenesis in vertebrates | 1.42 | 0.05 |
| |
| 23 | RAR activation | 1.41 | 0.04 |
| |
| 24 | Choline degradation I | 1.4 | 0.5 |
| |
| 25 | Sulfate activation for sulfonation | 1.4 | 0.5 |
| |
| 26 | Mismatch repair in eukaryotes | 1.4 | 0.13 |
|
|
| 27 | Glioma signaling | 1.37 | 0.05 |
|
|
| 28 | Netrin signaling | 1.36 | 0.08 |
| |
| 29 | Cellular effects of sildenafil (Viagra) | 1.33 | 0.05 |
|
|
| 30 | GNRH signaling | 1.33 | 0.05 |
|
|
| 31 | Protein kinase A signaling | 1.31 | 0.03 |
|
|
| 32 | Ovarian cancer signaling | 1.31 | 0.05 |
|
|
| 33 | Colorectal cancer metastasis signaling | 1.3 | 0.04 |
|
|
| 34 | Agrin interactions at neuromuscular junction | 1.3 | 0.06 |
|
|
| 35 | Growth hormone signaling | 1.3 | 0.06 |
|
|
Methylation marks that partially mediate the association between pesticide exposure and leptin and body fat accumulation in PON1-192 R-allele carriers
| Outcome | IlmnID | Nearest gene symbol | Gene name | Direction of methylation in exposed R carriers | Diseases | Significance of causal mediation effect ( |
|---|---|---|---|---|---|---|
| Leptin | cg03366858 |
| Low density lipoprotein receptor-related protein 8, apolipoprotein e receptor | Hyper | Myocardial infarction (0.22)|nerve degeneration (0.21)|Myocardial infarction, susceptibility to, 1 (finding) (0.2) | 0.02 |
| Leptin | cg18202502 |
| Low density lipoprotein receptor-related protein 8, apolipoprotein e receptor | Hyper | Myocardial infarction (0.22) | nerve degeneration (0.21)|myocardial infarction, susceptibility to, 1 (finding) (0.2) | 0.024 |
| Delta BMI | cg00810945 |
| Ubiquinol-cytochrome c reductase core protein II | Hypo | Mitochondrial complex iii deficiency, nuclear type 5 (0.41) | obesity (0.21) | 0.138 |
| Delta BMI | cg06337557 |
| Melatonin receptor 1B | Hypo | Diabetes mellitus, Type 2 (0.26)|polycystic ovary syndrome (0.21) | child development disorders, pervasive (0.21)|acute pancreatitis (0.1) | 0.032 |
| Delta BMI | cg14152613 |
| Fatty acid-binding protein 4, adipocyte | Hyper | Carcinoma (0.21)|mammary neoplasms, experimental (0.21) | mammary neoplasms, animal (0.21)|insulin resistance (0.1)|erectile dysfunction (0.1)|diabetes mellitus, experimental (0.1) | 0.068 |
| Delta BMI | cg15134033 |
| Glutamate receptor, ionotropic, N-methyl D-aspartate 2A | Hypo | Epilepsy (0.21)|colorectal neoplasms (0.21)|epilepsy, rolandic (0.21)|melanoma (0.21)|landau-kleffner syndrome (0.21)|autistic disorder (0.21)|morphine dependence (0.21)|language development disorders (0.21)|epilepsy, focal, with speech disorder and with or without mental retardation (0.21)|speech disorders (0.21)|substance withdrawal syndrome (0.21)|rolandic epilepsy, mental retardation, and speech dyspraxia, autosomal dominant (0.2)|reperfusion injury (0.1)|hypoxia-ischemia, brain (0.1)|sepsis (0.1)|fetal growth retardation (0.1)|central nervous system viral diseases (0.1)|placental insufficiency (0.1) | 0.144 |
| Delta BMI | cg18202502 |
| Low density lipoprotein receptor-related protein 8, apolipoprotein e receptor | Hyper | Myocardial infarction (0.22)|nerve degeneration (0.21)|myocardial infarction, susceptibility to, 1 (finding) (0.2) | 0.026 |
| Bodyfat | cg00810945 |
| Ubiquinol-cytochrome c reductase core protein II | Hypo | Mitochondrial complex iii deficiency, nuclear type 5 (0.41)|obesity (0.21) | 0.174 |
| Bodyfat | cg03366858 |
| Low density lipoprotein receptor-related protein 8, apolipoprotein e receptor | Hyper | Myocardial infarction (0.22)|nerve degeneration (0.21)|myocardial infarction, susceptibility to, 1 (finding) (0.2) | <0.001 |
| Bodyfat | cg18202502 |
| Low density lipoprotein receptor-related protein 8, apolipoprotein e receptor | Hyper | Myocardial infarction (0.22)|nerve degeneration (0.21)|myocardial infarction, susceptibility to, 1 (finding) (0.2) | <0.001 |
Only the subset of genes for which associations with metabolic disease have been reported is listed. DisGeNET Score—indicating reliability of the gene disease associations—is included between brackets
Fig. 5Association between PON1 methylation and PON1 C-108T SNP. Individuals homozygous for the T allele showed higher methylation values (beta values) as compared with C-allele carriers. P values shown are those from the one-way ANOVA analysis
Fig. 6Association between PON1 activity and PON1 methylation. The P values of the main effect for methylation are displayed using the linear model PON1 activity ~ M value + PON1-192 genotype + sex. Red colored samples are PON1 192 R-allele carriers, and samples in blue are children with the PON1 192QQ genotype